- $2.34bn
- $1.08bn
- $548.51m
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
Hutchmed Initiates Global Trial Of Hmpl: A830
Hutchmed Climbs After On Initiating Hmpl: A830 global trial in solid tumors
Brief: Hutchmed (China) Initiates Global Phase A Trial Of HMPL-A830 In Advanced Solid Tumors
Data to be Presented at ESMO 2026
UK Stocks-Factors to watch on September 3 (updated)
Hutchmed Licenses Kras: EGFR-Antibody to GSK
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug (updated)
HUTCHMED jumps most in near 4 years on GSK licensing deal
UK Stocks-Factors to watch on September 3
HUTCHMED (China) signs exclusive licensing deal with GSK for investigational cancer drug
Brief: Hutchmed Announces Licensing Agreement With GSK For Kras-Egfr-Antibody Conjugate Cancer Therapy
UK Stocks-Factors to watch on September 1 (updated)
AstraZeneca-Hutchmed drug combination shows promise in advanced lung cancer study (updated)
SANOVO trial demonstrated significant PFS benefit
Brief: HUTCHMED (China) Announces NMPA Conditional Approval For ATLED In China
NMPA Approval for ATLED® (Fanregratinib) for ICC
Brief: Hutchmed (China) Announces NMPA Conditional Approval For Atled (Fantegratinib) In China
Announcement pursuant to AIM Rule 17 Schedule 2(g)